Chemed (NYS: CHE) is expected to report Q4 earnings on Feb. 18. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Chemed's revenues will grow 4.1% and EPS will increase 5.7%.
The average estimate for revenue is $364.5 million. On the bottom line, the average EPS estimate is $1.48.
Last quarter, Chemed reported revenue of $354.4 million. GAAP reported sales were 3.8% higher than the prior-year quarter's $341.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS of $1.07 for Q3 were 2.9% higher than the prior-year quarter's $1.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 27.6%, 60 basis points worse than the prior-year quarter. Operating margin was 10.5%, 160 basis points worse than the prior-year quarter. Net margin was 5.9%, 50 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.43 billion. The average EPS estimate is $5.22.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 100 members out of 114 rating the stock outperform, and 14 members rating it underperform. Among 40 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Chemed a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $68.75.
Is Chemed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
Add Chemed to My Watchlist.
The article What Does Wall Street See for Chemed's Q4? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.